Citation Impact
Citing Papers
Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation
2006
A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein
2007 StandoutNobel
Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers
2008
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
2004 StandoutScience
Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy
2006
Designed protein logic to target cells with precise combinations of surface antigens
2020 StandoutScienceNobel
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
2003
Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects
2004
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
2004
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
2003
ErbB Receptors: Directing Key Signaling Networks Throughout Life
2004
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation
2004
Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB-2 Inhibitor Lapatinib
2004
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
2007 Nature
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003
Herceptin: mechanisms of action and resistance
2005
Hallmarks of Cancer: The Next Generation
2011 Standout
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
2002
(−)-Epigallocatechin Gallate and Polyphenon E Inhibit Growth and Activation of the Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Signaling Pathways in Human Colon Cancer Cells
2005
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
2000
EGFR associated expression profiles vary with breast tumor subtype
2007
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
2016
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Gefitinib (“Iressa”, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug Resistance
2005
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
2003
EGFR Antagonists in Cancer Treatment
2008 Standout
ErbB-targeted therapeutic approaches in human cancer
2003
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model
2002
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
2005
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
2007 StandoutNature
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
2008 StandoutNature
Tumor-Associated Macrophages in Breast Cancer
2002
Clinical translation of angiogenesis inhibitors
2002 Standout
Comparing antibody and small-molecule therapies for cancer
2006
Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells
2003
Oncogenic kinase signalling
2001 StandoutNature
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
2003
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Molecular mechanisms of drug resistance
2005
Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor
2007
Targeting the PI3K-Akt pathway in human cancer
2003
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Antithrombotic Therapy for VTE Disease
2016 Standout
The type III epidermal growth factor receptor mutation
2001
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer
2005
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
Concerns in using multi-detector computed tomography for diagnosing pulmonary embolism in daily practice. A cross-sectional analysis using expert opinion as reference standard
2012
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
2008
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
2008
From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
2000
Tyrosine kinases as targets in cancer therapy – successes and failures
2003
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
2005
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
2006
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells
2007
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
2006
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era
2002
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
2007 StandoutNature
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Cetuximab in advanced non-small cell lung cancer
2006
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
2005
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF‐κB and AP‐1 activation and IL‐8 and VEGF expression in human head and neck squamous cell carcinoma lines
2002
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis
2009
Gefitinib — a novel targeted approach to treating cancer
2004
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Targeting epidermal growth factor receptor—are we missing the mark?
2003
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Resistance in the anti-angiogenic era: nay-saying or a word of caution?
2003
Cancer immunotherapy comes of age
2011 StandoutNature
ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
2005
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
2005 StandoutNature
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
2003
Revealing the world of RNA interference
2004 StandoutNatureNobel
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
Proapoptotische Therapie mit Oblimersen (bcl-2-Antisense-Oligonukleotid) – Übersicht über präklinische und klinische Daten
2003
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
2002
Cancer prevention by tea: animal studies, molecular mechanisms and human relevance
2009 Standout
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
2001
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models
2004
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
2002
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Gefitinib for non-small-cell lung cancer treatment
2011
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
2007
Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme
2002
Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations
2006
Angiogenesis as a therapeutic target
2005 StandoutNature
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
2001
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells
2005
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
2009
Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin
2001
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
2004
BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
2025
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
2007
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
2002
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
2003
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
2007
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
2002
Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt
2007
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
2000
Role of transforming growth factor-α in von Hippel– Lindau (VHL) −/− clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
2001
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
2001
The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro
2003
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
2006
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
2004
Role of transforming growth factor-α in von Hippel– Lindau\n (VHL)−/− clear cell renal carcinoma cell proliferation: A\n possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
2001
Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)
2005
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
2001
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
2004
Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
2007
Progress in the Delivery of Therapeutic Oligonucleotides: Organ/Cellular Distribution and Targeted Delivery of OligonucleotidesIn Vivo
2003
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non–Small-Cell Lung Cancer
2002
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
2005
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
2004
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
2004
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
2002
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
2002
Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein
2005
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis
2012
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
2005
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
2005
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts
2005
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
2002
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
2007
Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
2003
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
2002
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
2005
Cancer Genome Landscapes
2013 StandoutScience
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
2005
Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck
2005
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
2002
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
2005
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
2007
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
2003
Gefitinib reverses breast cancer resistance protein–mediated drug resistance
2004
Site-Specific Conjugation of Boron-Containing Dendrimers to Anti-EGF Receptor Monoclonal Antibody Cetuximab (IMC-C225) and Its Evaluation as a Potential Delivery Agent for Neutron Capture Therapy
2003
Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition
2006
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
2003
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
2005
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
2001
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
2004
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
2002
Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
2005
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
2004
Works of Roberto Bianco being referenced
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
2008
Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
2013
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
2001
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model
2004
Cooperative Inhibition of Renal Cancer Growth by Anti-Epidermal Growth Factor Receptor Antibody and Protein Kinase A Antisense Oligonucleotide
1998
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
2005
Interobserver agreement in the interpretation of computed tomography in acute pulmonary embolism
2009
Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases
2006
A novelMDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer
2000
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
2007
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
2003
Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
2005
Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
2000
Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
1999
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
2000
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
2000
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
1999
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
2001
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor
2005
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
2004
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
2000
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
2002
Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
2001